Press release
Chagas Disease (American Trypanosomiasis) Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results
Download the sample report @ https://www.pharmaproff.com/request-sample/1056
Chagas disease presents itself in two phases including acute and chronic phase. The initial acute phase lasts for about two months after infection.
Get the detailed analysis @ https://www.pharmaproff.com/report/chagas-diseasetherapeutics-pipeline-analysis
The acute phase represents a high number of parasites circulation in the blood but in most cases the symptoms are absent or mild and unspecific. In less than 50% of people bitten by a triatomine bug, characteristic first visible signs can be a skin lesion or a purplish swelling of the lids of one eye.
Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1056
During the chronic phase, the parasites are hidden mainly in the heart and digestive muscles. It has been observed that upto 30% of patients suffer from cardiac disorders and up to 10% suffer from digestive (typically enlargement of the esophagus or colon) disorders, neurological disorders or mixed alterations.
The drug candidates of Chagas disease pipeline include, but not limited to, Posaconazole, Fexinidazole, and others. Some of the companies having drugs in the Chagas Disease (American Trypanosomiasis) pipeline includes Bayer AG, Eisai Co., Ltd., GlaxoSmithKline Plc, Merck & Co., Inc., and others.
• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chagas Disease (American Trypanosomiasis) Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results here
News-ID: 1693414 • Views: …
More Releases from Pharma Proff
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates.
IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to…
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates.
Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete…
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome.
Download the sample report at: https://www.pharmaproff.com/request-sample/1189
Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in…
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances…
More Releases for Chagas
Chagas Disease Market Emerging Trends and Growth Prospects 2034
Introduction
Chagas disease, also known as American trypanosomiasis, is a potentially life-threatening parasitic illness caused by Trypanosoma cruzi. It is transmitted primarily through triatomine bugs (kissing bugs), blood transfusions, congenital infections, or contaminated food. Once considered confined to Latin America, globalization, migration, and increased travel have made Chagas disease a global public health concern.
While millions are infected worldwide, the disease remains classified as a neglected tropical disease (NTD), with limited treatment…
Chagas Disease Treatment Market: An In-Depth Analysis
The global Chagas Disease Treatment Market was valued at approximately USD 450 million in 2024 and is projected to reach around USD 700 million by 2033, growing at a compound annual growth rate (CAGR) of 5.5% from 2026 to 2033 .
Chagas Disease Treatment Market Overview
Chagas disease, caused by the Trypanosoma cruzi parasite, remains a significant public health challenge, particularly in Latin America. The market's growth is driven by increasing awareness,…
Chagas Disease Drug Market Size, Share, Growth Forecast 2023-2032
Chagas disease, caused by the parasite Trypanosoma cruzi, remains a significant public health concern, particularly in Latin America. With an estimated 6 to 7 million people worldwide affected by this neglected tropical disease, the demand for effective treatments has spurred the growth of the Chagas Disease Drug Market. As of 2022, the market size stood at a commendable USD 265.2 million, and projections indicate a robust expansion, with expectations to…
2018 – 2024 Chagas Disease Management Market | Global Industry Report
2018 – 2024 Chagas Disease Management Market | Global Industry Report
A Recent Market Study On Chagas Disease And Its Current Trends And Future Insights
Chagas disease or American trypanosomiasis is a tropical parasitic disease caused by Trypanosoma cruzi. It is transmitted by kissing bugs or triatomine bugs. It can also be transmitted through blood transfusions, in pregnancy, and organ transplantation. In early stage of the Chagas disease, the symptoms include swollen…
Chagas Disease Treatment Market Global Industry Insights, and Forecast till 2025
Chagas disease is an endemic in 21 Latin American countries caused by kinetoplastid protozoan parasite, Trypanosoma cruzi, primarily transmitted by large, blood-sucking reduviid insects widely known as 'the kissing bugs'. Moreover, the disease can be transferred through other means such as blood transfusion, organ transplantation, as well as congenital and oral transmissions. The recent past has witnessed spread of Chagas disease to developed economies such as Europe and North America,…
Chagas Disease Treatment Market - Global Industry Insights, and Forecast till 20 …
Chagas disease is an endemic in 21 Latin American countries caused by kinetoplastid protozoan parasite, Trypanosoma cruzi, primarily transmitted by large, blood-sucking reduviid insects widely known as 'the kissing bugs'. Moreover, the disease can be transferred through other means such as blood transfusion, organ transplantation, as well as congenital and oral transmissions. The recent past has witnessed spread of Chagas disease to developed economies such as Europe and North America,…
